Nutritional management of cystic fibrosis patients

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 10, Issue 3, 2007, Pages 348-354

  Kalnins, Daina ^a   Durie, Peter R ^a   Pencharz, Paul ^a,b,c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c Division of Gastroenterology Hepatology and Nutrition   (Canada)

^d Research Institute   (Canada)

Author keywords

Bone health; Enzyme therapy; Fecal elastase; Nutrient maldigestion; Vitamin D; Vitamin K

Indexed keywords

7 DEHYDROCHOLESTEROL; BICARBONATE; CALCIUM; COLECALCIFEROL; CYTOKINE; ERGOCALCIFEROL; MONOCLONAL ANTIBODY; OMEPRAZOLE; PANCREAS ENZYME; PANCREATIC ELASTASE; PARATHYROID HORMONE; TRANSMEMBRANE CONDUCTANCE REGULATOR; VITAMIN D; VITAMIN K GROUP;

BONE DENSITY; CALCIUM DEFICIENCY; CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG MEGADOSE; ENTERIC COATED TABLET; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REPLACEMENT; FECES ANALYSIS; GENE MUTATION; HUMAN; INTESTINE; LIPID ABSORPTION; LIPID METABOLISM; MALABSORPTION; NEWBORN SCREENING; NUTRITIONAL SUPPORT; PANCREAS INSUFFICIENCY; PH MEASUREMENT; PNEUMONIA; REVIEW; SCREENING TEST; VITAMIN D DEFICIENCY; VITAMIN K DEFICIENCY; VITAMIN SUPPLEMENTATION;

BONE AND BONES; CYSTIC FIBROSIS; DIETARY FATS; EXOCRINE PANCREATIC INSUFFICIENCY; FECES; HUMANS; PANCREAS; PANCREATIC ELASTASE; PANCREATIC FUNCTION TESTS;

EID: 34247160331     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/MCO.0b013e3280a94f80     Document Type: Review

References (56)

1. Borowitz DS, Grand RJ, Durie PR. Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. Consensus Committee. J Pediatr 1995; 127:681-684.
2. Sinaasappel M, Stern M, Littlewood J, et al. Nutrition in patients with cystic fibrosis: a European Consensus. J Cyst Fibros 2002; 1:51-75.
3. Anthony H, Collins CE, Davidson G, et al. Pancreatic enzyme replacement therapy in cystic fibrosis: Australian guidelines. Pediatric Gastroenterological Society and the Dietitians Association of Australia. J Paediatr Child Health 1999; 35:125-129.
4. Dorlochter L, Aksnes L, Fluge G. Faecal elastase-1 and fat-soluble vitamin profiles in patients with cystic fibrosis in Western Norway. Eur J Nutr 2002; 41:148-152.
5. Cohen JR, Schall JI, Ittenbach RF, et al. Fecal elastase: pancreatic status verification and influence on nutritional status in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 2005; 40:438-444.
6. Walkowiak J, Nousia-Arvanitakis S, Cade A, et al. Fecal elastase-1 cut-off levels in the assessment of exocrine pancreatic function in cystic fibrosis. J Cyst Fibros 2002; 1:260-264.
7. Beharry S, Ellis L, Corey M, et al. How useful is fecal pancreatic elastase 1 as a marker of exocrine pancreatic disease? J Pediatr 2002; 141:84-90.
8. Cade A, Walters MP, McGinley N, et al. Evaluation of fecal pancreatic elastase-1 as a measure of pancreatic exocrine function in children with cystic fibrosis. Pediatr Pulmonol 2000; 29:172-176.
9. Walkowiak J, Nousia-Arvanitakis S, Agguridaki C, et al. Longitudinal follow-up of exocrine pancreatic function in pancreatic sufficient cystic fibrosis patients using the fecal elastase-1 test. J Pediatr Gastroenterol Nutr 2003; 36:474-478.
10. Borowitz D, Baker SS, Duffy L, et al. Use of fecal elastase-1 to classify pancreatic status in patients with cystic fibrosis. J Pediatr 2004; 145:322-326.
11. Abdel Rahman H, Abdul Wahab A, Abdel Rahman MO, et al. Faecal elastase-1 concentration in cystic fibrosis patients with CFTR I1234V mutation. Acta Paediatr 2006; 95:1066-1069.
12. Walkowiak J, Sands D, Nowakowska A, et al. Early decline of pancreatic function in cystic fibrosis patients with class 1 or 2 CFTR mutations. J Pediatr Gastroenterol Nutr 2005; 40:199-201.
13. Carroccio A, Verghi F, Santini B, et al. Diagnostic accuracy of fecal elastase 1 assay in patients with pancreatic maldigestion or intestinal malabsorption: a collaborative study of the Italian Society of Pediatric Gastroenterology and Hepatology. Dig Dis Sci 2001; 46:1335-1342.
14. Schneider A, Funk B, Caspary W, et al. Monoclonal versus polyclonal ELISA for assessment of fecal elastase concentration: pitfalls of a new assay. Clin Chem 2005; 51:1052-1054.
15. Miendje Y, Maisin D, Sipewa MJ, et al. Polyclonal versus monoclonal ELISA for the determination of fecal elastase 1: diagnostic value in cystic fibrosis and chronic pancreatic insufficiency. Clin Lab 2004; 50:419-424.
16. Nissler K, Von Katte I, Huebner A, et al. Pancreatic elastase 1 in feces of preterm and term infants. J Pediatr Gastroenterol Nutr 2001; 33:28-31.
17. Kori M, Maayan-Metzger A, Shamir R, et al. Faecal elastase 1 levels in premature and full term infants. Arch Dis Child Fetal Neonatal Ed 2003; 88:F106-F108.
18. Fischer B, Hoh S, Wehler M, et al. Faecal elastase-1: lyophilization of stool samples prevents false low results in diarrhoea. Scand J Gastroenterol 2001; 36:771-774.
19. Koscik RL, Farrell PM, Kosorok MR, et al. Cognitive function of children with cystic fibrosis: deleterious effect of early malnutrition. Pediatrics 2004; 113:1549-1558.
20. Bronstein MN, Sokol RJ, Abman SH, et al. Pancreatic insufficiency, growth, and nutrition in infants identified by newborn screening as having cystic fibrosis. J Pediatr 1992; 120 (4 Pt 1):533-540.
21. Borowitz D, Goss CH, Stevens C, et al. Safety and preliminary clinical activity of a novel pancreatic enzyme preparation in pancreatic insufficient cystic fibrosis patients. Pancreas 2006; 32:258-263.
22. Durie P, Kalnins D, Ellis L. Uses and abuses of enzyme therapy in cystic fibrosis. J R Soc Med 1998; 91 (Suppl 34):2-13.
23. Borowitz D, Durie PR, Clarke LL, et al. Gastrointestinal outcomes and confounders in cystic fibrosis. J Pediatr Gastroenterol Nutr 2005; 41:273-285.
24. Butt AM, Ip W, Ellis L, et al. The fate of exogenous enzymes in patients with cystic fibrosis and pancreatic insufficiency (abstr). J Pediatr Gastroenterol Nutr 2001; 33:391.
25. Laiho KM, Gavin J, Murphy JL, et al. Maldigestion and malabsorption of 13C labelled tripalmitin in gastrostomy-fed patients with cystic fibrosis. Clin Nutr 2004; 23:347-353.
26. Peretti N, Roy CC, Drouin E, et al. Abnormal intracellular lipid processing contributes to fat malabsorption in cystic fibrosis patients. Am J Physiol Gastrointest Liver Physiol 2006; 290:G609-G615.
27. Kalnins D, Corey M, Ellis L, et al. Combining unprotected pancreatic enzymes with pH-sensitive enteric-coated microspheres does not improve nutrient digestion in patients with cystic fibrosis. J Pediatr 2005; 146:489-493.
28. Kalnins D, Ellis L, Corey M, et al. Enteric-coated pancreatic enzyme with bicarbonate is equal to standard enteric-coated enzyme in treating malabsorption in cystic fibrosis. J Pediatr Gastroenterol Nutr 2006; 42:256-261. A bicarbonate containing enzyme was no more efficacious than regular entericcoated enzymes in reducing fat absorption, with both resulting in 20% fat malabsorption in a select group of patients.
29. Baker SS, Borowitz D, Duffy L, et al. Pancreatic enzyme therapy and clinical outcomes in patients with cystic fibrosis. J Pediatr 2005; 146:189-193.
30. Kalnins D, Corey M, Ellis L, et al. Failure of conventional strategies to improve nutritional status in malnourished adolescents and adults with cystic fibrosis. J Pediatr 2005; 147:399-401.
31. •].
32. Aris RM, Merkel PA, Bachrach LK, et al. Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab 2005; 90:1888-1896.
33. Conway SP, Wolfe SP, Brownlee KG, et al. Vitamin K status among children with cystic fibrosis and its relationship to bone mineral density and bone turnover. Pediatrics 2005; 115:1325-1331.
34. Buntain HM, Schluter PJ, Bell SC, et al. Controlled longitudinal study of bone mass accrual in children and adolescents with cystic fibrosis. Thorax 2006; 61:146-154. The authors reported suboptimal bone mass accrual in adolescents, using areal BMD (BMC/bone area) adjusted for age. Lean tissue and deteriorating lung function were associated with reduced gain in bone mass. An excellent discussion on bone health is provided.
35. Buntain HM, Greer RM, Schluter PJ, et al. Bone mineral density in Australian children, adolescents and adults with cystic fibrosis: a controlled cross sectional study. Thorax 2004; 59:149-155.
36. Khosla S, Melton LJ 3rd, Dekutoski MB, et al. Incidence of childhood distal forearm fractures over 30 years: a population-based study. JAMA 2003; 290:1479-1485.
37. Goulding A, Rockell JE, Black RE, et al. Children who avoid drinking cow's milk are at increased risk for prepubertal bone fractures. J Am Diet Assoc 2004; 104:250-253.
38. Rovner AJ, Zemel BS, Leonard MB, et al. Mild to moderate cystic fibrosis is not associated with increased fracture risk in children and adolescents. J Pediatr 2005; 147:327-331.
39. Stephenson A, Jamal S, Dowdell T, et al. Prevalence of vertebral fractures in adults with cystic fibrosis and their relationship to bone mineral density. Chest 2006; 130:539-544.
40. Cheng S, Lyytikainen A, Kroger H, et al. Effects of calcium, dairy product, and vitamin D supplementation on bone mass accrual and body composition in 10-12-y-old girls: a 2-y randomized trial. Am J Clin Nutr 2005; 82:1115-1126; quiz 1147-8.
41. Vatanparast H, Baxter-Jones A, Faulkner RA, et al. Positive effects of vegetable and fruit consumption and calcium intake on bone mineral accrual in boys during growth from childhood to adolescence: the University of Saskatchewan Pediatric Bone Mineral Accrual Study. Am J Clin Nutr 2005; 82:700-706.
42. Matkovic V, Goel PK, Badenhop-Stevens NE, et al. Calcium supplementation and bone mineral density in females from childhood to young adulthood: a randomized controlled trial. Am J Clin Nutr 2005; 81:175-188.
43. Winzenberg TM, Shaw K, Fryer J, et al. Calcium supplementation for improving bone mineral density in children. Cochrane Database Syst Rev 2006; (2):CD005119.
44. Schulze KJ, O'Brien KO, Germain-Lee EL, et al. Endogenous fecal losses of calcium compromise calcium balance in pancreatic-insufficient girls with cystic fibrosis. J Pediatr 2003; 143:765-771.
45. Gronowitz E, Garemo M, Lindblad A, et al. Decreased bone mineral density in normal-growing patients with cystic fibrosis. Acta Paediatr 2003; 92:688-693.
46. Gronowitz E, Mellstrom D, Strandvik B. Normal annual increase of bone mineral density during two years in patients with cystic fibrosis. Pediatrics 2004; 114:435-442.
47. Aris RM, Neuringer IP, Weiner MA, et al. Severe osteoporosis before and after lung transplantation. Chest 1996; 109:1176-1183.
48. King SJ, Topliss DJ, Kotsimbos T, et al. Reduced bone density in cystic fibrosis: DeltaF508 mutation is an independent risk factor. Eur Respir J 2005; 25:54-61.
49. Vieth R. What is the optimal vitamin D status for health? Prog Biophys Mol Biol 2006; 92:26-32.
50. Boyle MP, Noschese ML, Watts SL, et al. Failure of high-dose ergocalciferol to correct vitamin D deficiency in adults with cystic fibrosis. Am J Respir Crit Care Med 2005; 172:212-217.
51. Houghton LA, Vieth R. The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am J Clin Nutr 2006; 84:694-697.
52. Gronowitz E, Larko O, Gilljam M, et al. Ultraviolet B radiation improves serum levels of vitamin D in patients with cystic fibrosis. Acta Paediatr 2005; 94:547-552.
53. Wilson DC, Rashid M, Durie PR, et al. Treatment of vitamin K deficiency in cystic fibrosis: Effectiveness of a daily fat-soluble vitamin combination. J Pediatr 2001; 138:851-855.
54. Temme KE, Schall JI, Boctor D, et al. Relationship of serum vitamin K status to supplemental vitamin K intake in children, adolescents and young adults with cystic fibrosis [abstract]. Pediatr Pulmonol 2006; 29 (Suppl):390.
55. Nicolaidou P, Stavrinadis I, Loukou I, et al. The effect of vitamin K supplementation on biochemical markers of bone formation in children and adolescents with cystic fibrosis. Eur J Pediatr 2006; 165:540-545.
56. Zindani GN, Streetman DD, Streetman DS, et al. Adherence to treatment in children and adolescent patients with cystic fibrosis. J Adolesc Health 2006; 38:13-17.